Home Bladder cancer screening: The new selection and prediction model
Article Open Access

Bladder cancer screening: The new selection and prediction model

  • Vladan Radosavljevic EMAIL logo and Natasa Milic
Published/Copyright: June 16, 2023

Abstract

The objective of this study was to offer new approach for selection of persons with asymptomatic bladder cancer (BC) and highly risky persons for the BC occurrence. Also, it is a part of the BC screening protocol (study is ongoing). Study populations were 100 newly diagnosed (diagnosis maximum 1-year old) males with BC and 100 matched (by sex and age ±5 years) controls (not oncology patients from the same hospital). A hospital based, matched case–control study was done. Statistical analysis comprised of four steps: t-test, univariate logistic regression, multivariate logistic regression, and scoring. The fifth step comprised of two changes, deleting one variable and addition of another variable. Six variables were statistically significant: Caucasian men over 45 years age, tobacco smoking over 40 pack-years, occupational and/or environmental exposure to the proved BC carcinogens over 20 years, macrohematuria, difficulty urinating, BC in relatives up to fourth degree of kinships, and they were used for an easy and fast selection of the individuals with high risk for BC occurrence and BC asymptomatic patients (optimal selection at the population level). The final results showed highly significant probability (p < 0.001), with area under ROC curve of 0.913, negative predictive values of 89.7% (95% CI 10.3–100%), and a specificity of 78%. Positive predictive value was 80.5% (95% CI 19.5–100%) and a sensitivity of 91%. It is possible to recruit asymptomatic BC patients (primary prevention) by using this model, as well as persons with high risk for BC occurrence (primordial prevention). This study is the first part of the BC screening protocol and the second part of the BC screening protocol study is ongoing (urine analysis).

1 Introduction

Bladder cancer (BC) is among the most frequent malignancies worldwide, especially in Europe and North America, elderly men, Caucasians, smokers, and occupationally exposed people. Due to the growth of the global population, both in terms of size and age, the increase of both incidence and prevalence of BC patients may be expected [1,2,3]. Over 1.7 million people live with BC worldwide. Currently, people at the age of 60+ represent approximately 13.7% of the world population, varying from 25% in Europe to 5% in Africa. Population at the age of 60+ is rising from current over 970 million to 1.4 billion by 2030 and 2.1 billion by 2050 [4]. In less developed countries the incidence of BC is increasing because of high rate of smoking [3]. Over 95% of BCs are transitiocellulare pathohistological type, while the remainder up to 5% are rare subtypes such as squamocellulare, adenocarcinoma, sarcoma, and metastases to the bladder [2].

Worldwide, the lifetime risk of getting BC is 1.1% in men and 0.27% in women [1]. The lifetime risk is considerably higher in most developed countries, such as the US (lifetime risk in men and women is 3.9 and 1.2%, respectively) [1]. Worldwide, approximately 213,000 patients died from BC in 2020 (2.1% of all cancer sites, for men 4.4%), and incidence was over 573,000 patients (3.0% of all cancer sites, for men 3.9%). BC is more common in men than in women, with respective incidence and mortality rates of 9.5 and 3.3 per 100,000 among men, which are approximately four times higher than among women globally [5].

BC is the most expensive cancer for treatment, due to recurrent nature of disease, expensive disease monitoring, and curing by trimodal therapy: surgery, chemotherapy, and radiotherapy [3,6]. Non-muscle invasive bladder cancer (NMIBC) accounts for about 75% of newly diagnosed BCs. It is limited to mucosa (stage Ta) or submucosa (stage T1). NMIBC recurs in 50–70% of the cases. More progressive malignancy occurs in 10–15% of the cases [7].

There is no officially or widely accepted method for BC screening. Due to the low BC incidence in general population, selection of asymptomatic BC patients from the general population is the main problem for BC screening [6,8]. To the best of our knowledge, this approach was used for the first time ever. This model uses BC screening for two purposes: primordial BC prevention and primary BC prevention. Primordial prevention includes detection of persons with high risk for the BC occurrence. Primary prevention includes detection of persons with early BC (NMIBC).

Urinary biomarkers showed 12–26% false-positive results in respondents when used for BC screening, and combined with biomarkers’ limited sensitivity, could present a missed diagnosis in up to 43% respondents. The main and the most studied urinary biomarkers and their effectiveness are nuclear matrix proteins (NMP)22 Bladder Cancer ELISA-test (sensitivity of 69% and a specificity of 77%), NMP22 BladderChek tests (sensitivity of 52–59% and a specificity of 87–89%), Bladder Tumour Antigen (BTA) Stat-test (sensitivity 57–82% and a specificity of 68–93%), BTA TRAK-test (sensitivity of 66–77% and a specificity ranging from 5 to 75%), UroVysion test is a multicolour fluorescent in situ hybridization (FISH) assay (sensitivity ranges between 69 and 87% and a specificity between 89 and 96%), ImmunoCyt assay (uCyt+) with a sensitivity ranging from 60 to 100% and a specificity of 75–84%, URO17™ urine test (sensitivity of 100% and specificity of 96%), BLCA4 (sensitivity of 89–96% with a specificity of 95–100%), CellDetect assay (sensitivity of 84% and the specificity of also 84%), and aurora A kinase (AURKA)-FISH test (sensitivity 87% and 96.6% specificity). DNA-based urine biomarkers (DNA Methylation) are GSTP1, RARb2, APC genes (sensitivity 62% and specificity 89%), TWIST1 and NID2 genes (sensitivity 79% and specificity 63%), POU4F2 and PCDH17 genes (sensitivity 90% and specificity 94%), CFTR, SALL3/TWIST1 genes (sensitivity 84% and specificity 68%), and HDAC3 genes (sensitivity 89% and specificity 63%). Genetic alterations include both DNA mutational analysis – urinary Telomerase reverse transcriptase promoter mutations (sensitivity of 80.5% and specificity of 89.8%) and microsatellite analysis – a PCR analysis of DNA in exfoliated urine cells (sensitivity range from 72 to 97% and the specificity between 80 and 100%). Urinary tumour RNAs include MicroRNAs (miRNAs) which can be derived from a range of specimens – supernatant, urine sediment, and voided urine. The most important are 6 miRNAs = miR-187 + miR-18a + miR-25 + miR-142-3p + miR140-5p + miR204 (sensitivity 85% and specificity 87%), miR-99a + miR-125b (sensitivity 87% and specificity 81%), miR-96 + cytology (sensitivity 87% and specificity 87%), and 25 target diagnostic miRNA signature (sensitivity 87% and specificity 100%). Finally, multigene panels involve DNA, mRNA, and epigenetic targets, and the most important among them is Cxbladder with genes: IGFBP5, HOXA13, MDK, CDK1, and CXCR2 (sensitivity 82% in patients with hematuria and specificity 90%) [9].

miRNAs are single stranded, non-coding RNAs (20–25 nucleotides) that are hypothesized to regulate gene expression at the post-transcriptional level. The results of the present study indicated that miR-200, miR-145, and miR-21 may function as oncogenes and have a potential to serve as an early non-invasive diagnostic biomarkers and therapeutic targets for treatment of BC. Authors suggest that miR-200, miR-145, and miR-21 may function as diagnostic and prognostic markers as well as possible therapeutic targets for treatment of BC [10,11]. Identification of alterations in genes that are frequently mutated in BC appears to be a promising strategy for detecting disease from urine samples and reducing reliance on examination of the bladder via a telescopic camera inserted through the urethra (flexible cystoscopy has estimated sensitivity of 85% and specificity of 87%). Urinary DNA arguably yields the most robust tumour-specific information for non-invasive BC detection. Some authors described the development and validation of a non-invasive test for detection of BC based on error suppressed ultra-deep sequencing of somatic mutations in 23 genes in urinary DNA. The test has the potential to detect new cases of BC with high sensitivity and specificity [11,12].

Because of the low prevalence of BC in the general population (0.001%), even in elderly over the age of 50 (0.67–1.13%), followed by detecting a significant number of BC false positive results, mass screening is certainly not acceptable [13]. Therefore, introducing BC risk scoring in screening protocol seems to be very promising. Ideal screening candidates should be non-invasive, cheap, fast, friendly for use, highly sensitive, and highly specific.

In around 80% of BC patients the diagnosis was made at an age 65 or older, reflecting a disease course that occurs after several decades of exposure even if the exposure only lasted several years. BC is a prime candidate for prevention strategies as 80% of cases are attributable to known risk factors [2].

2 Patients and methods

A literature review was performed in the MEDLINE database. The focus of the literature search was for the period between January 1, 2014 and March 31, 2023, to obtain the necessary data for a retrospective analysis of the BC screening possibilities and attempts. The indicated period was reviewed because the author’s last published review article from the BC field was published in January 2014 [6].

The BC screening was the guiding question of the literature review. The types of reviewed literature were the original research articles as well as the review articles published in the English language in peer-reviewed journals and books. Criteria for inclusion in the review were the following keywords: bladder cancer, screening, cohort, research and population. The time period in which the search was carried out was between July 1, 2021 and March 31, 2023.

The Pubmed advanced search strategy was used for the article selection. Query box “All fields” was used, due to its comprehensiveness. Step one: bladder cancer AND screening = 2,139 full text references; terms to the query box: All fields. Step two: bladder cancer AND screening AND cohort = 181 full text references; terms to the query box: All fields. Step three: bladder cancer AND screening AND research = 740 full text references; terms to the query box: All fields. Step four: bladder cancer AND screening AND population = 205 full text references; terms to the query box: All fields. Two main criteria for the articles and books selection were scientific informativeness and scientific reliability. The first group consisted of a very large number of the papers that were rejected after consideration of the articles’ title. Numerous groups of articles were rejected from further review after studying the abstracts of the articles. The third group of articles was rejected after musing upon the articles’ methods and results. The fourth group of articles was discarded after detailed considering the entire article. Finally, the fifth group of articles was eliminated after reading and mutually comparing with other articles from the field.

This model has two aims: (1) selection of people with high risk for BC occurrence and (2) selection of patients with early BC. We structured interview according to both: proved BC risk factors and observing the most affected population. The focus of the interview was on Caucasian men over 45 years age, tobacco smoking, arsenic in drinking water, occupational exposure (intensity and duration), heredity (BC or other malignancy present in the first four kinship degrees), gross hematuria, genitourinary infections, benign prostate enlargement, and diabetes over 20 years duration. The remaining questions were about BC disease (time of the disease onset, clinical stadium, pathohistological findings). The total number of participants enrolled in the study was 200, and 100 of them had a history of BC. First group of 50 participants were randomly selected from January 2018 to August 2021, and the second group of 50 consecutive patients from September 2021 to December 2021. The patients were recruited from the Urology Clinic of the Military Medical Academy in Belgrade (Serbia). An experienced epidemiologist interviewed 50 patients while urologists interviewed another 50 patients. The same number of controls matched by sex and age (±5 years) were simultaneously interviewed from the same hospital as patients (rheumatology department, physical medicine and rehabilitation department, and cardiology department). At the cardiology department patients whose disease could be influenced by tobacco smoking were excluded. Statistical analysis comprised of four steps: t-test, univariate logistic regression, multivariate logistic regression, and scoring. The fifth step comprised of two changes, deleting one variable and addition in another variable.

The research related to human use has been complied with all the relevant national regulations, institutional policies and in accordance the tenets of the Helsinki Declaration, and has been approved by the Ethical Board of the Military Medical Academy on November 27, 2017. Before the interview, all participants provided informed consent for participation in the study.

3 Results

The mean age of patients in this study was 67.31 years, 83% of the patients were married.

3.1 Statistical analysis

Step 1. t-Test was applied on all variables (questions from the questionnaire) and statistically significant differences were found for level of education: high school and lower levels of education vs post-high school education or university level, p = 0.001; tobacco smoking over 40 pack-years vs less than 40 pack-years, p < 0.001; occupational exposure to the proved BC carcinogens over 20 years vs less than 20 years, p < 0.001; macrohematuria, p < 0.001; difficulty urinating, p < 0.001; and BC in relatives up to fourth degree of kinships, p = 0.002.

Step 2. Univariate logistic regressions on the previous six significant variables and results are presented in Table 1.

Table 1

Univariate logistic regression

Variables p OR 95% CI
Level of education 0.001 2.565 1.448–4.542
Tobacco smoking over 40 pack-years 0.000 6.303 3.374–11.775
Occupational exposure to the proved BC carcinogens over 20 years 0.000 4.758 2.131–10.626
Macrohematuria 0.000 34.810 15.836–76.517
Difficulty urinating 0.000 2.901 1.633–5.151
BC in relatives up to fourth degree of kinships 0.032 9.791 1.217–78.806

Step 3. Multivariate logistic regressions on the previous six significant variables. The results are presented in Table 2.

Table 2

Multivariate logistic regression

Variables p OR 95% CI
Tobacco smoking over 40 pack-years 0.000 4.696 1.966–11.218
Macrohematuria 0.000 30.101 12.544–72.232
Difficulty urinating 0.016 2.910 1.218–6.953
BC in relatives up to fourth degree of kinships 0.022 24.281 1.585–371.983

Step 4. Our preference was to make a method with high sensitivity. Thus, we decided to make Score 1 based on the univariate logistic regression results, e.g., based on six significant variables (Table 1). Cut-off was 10 for Score 1. Score 1 has highly significant probability (p < 0.001), with area under ROC curve of 0.913, negative predictive values (NPV) of 89.7% (95% CI 10.3–100%), and a specificity of 78% (Figure 1). Positive predictive values (PPV) was 80.5% (95% CI 19.5–100%) and a sensitivity of 91%.

Figure 1 
                  (Brief self-explanatory legend) Area under ROC curve of 0.913, NPV of 89.7% (95% CI 10.3–100%), and a specificity of 78%. PPV was 80.5% (95% CI 19.5–100%) and a sensitivity of 91%.
Figure 1

(Brief self-explanatory legend) Area under ROC curve of 0.913, NPV of 89.7% (95% CI 10.3–100%), and a specificity of 78%. PPV was 80.5% (95% CI 19.5–100%) and a sensitivity of 91%.

Step 5. Very recent and comprehensive literature reconsideration strongly suggested us to make some changes in the results of the univariate logistic regression [2,1116]. In the final model we decided to the delete variable “Level of education.” In the variable “Occupational exposure to the proved BC carcinogens over 20 years” add word environmental. Therefore, the issue should be “Occupational and/or environmental exposure to the proved BC carcinogens over 20 years” (Table 3).

Table 3

New selection and prediction model for BC occurrence

Variables P OR 95% CI
Tobacco smoking over 40 pack-years 0.000 6.303 3.374–11.775
Occupational and/or environmental exposure to the proved BC carcinogens over 20 years 0.000 4.758 2.131–10.626
Macrohematuria 0.000 34.810 15.836–76.517
Difficulty urinating 0.000 2.901 1.633–5.151
BC in relatives up to fourth degree of kinships 0.032 9.791 1.217–78.806

There was no statistical significance for the next variables: arsenic in drinking water ≥10 µg/L consumed over 20 years, genitourinary infections four or more times during lifetime, carcinomas of the upper urinary tract, diabetes mellitus (any type) over 20 years old diagnosis, benign tumours of the urinary bladder, and any other malignancies in relatives.

4 Discussion

Developing BC screening protocol is a great challenge. The time between screen detection and progression to advanced disease is a sufficiently lengthy period to allow for intervention. Some authors developed strategies for identifying high-risk populations for BC screening using the most frequent BC risk factors, and even more, defined risk score [17,8]. Screening studies have suggested a survival benefit amongst screened non-symptomatic populations with known risk factors, but it has not become a standard practice [18]. Chinese authors developed a prediction model of oesophageal cancer with good sensitivity based on eight epidemiological risk factors [19].

It is clear that a mass BC screening would only be feasible if restricted to a high-risk group [17]. Screening is the most successful method in high-risk populations and its cost efficacy may be reached if applied to a population with an incidence of BC >1–2% [8]. Risk prediction methods may optimize the universal endoscopic screening strategy, and show promising usefulness in screening practice [20].

4.1 The new selection and prediction model (variables)

4.1.1 Caucasian men over 45 years age

BC incidence disparities between genders are well documented [21]. Reasons for sex gap in BC incidence are differences in the following variables: smoking patterns, occupational exposures, access to health care, and delayed diagnosis in women (hematuria or lower urinary tract symptoms frequently being attributed to cystitis) [22]. Nations with the highest rates of BC are identified in Europe and North America, and the disease is four times more frequent in men than in women [2]. In less developed countries there is a lack of national and/or regional population-based cancer registries [1]. Black people in North America have a lower incidence rate for BC. Some researchers reported increasing trend of BC in Asian and Central and Eastern European developing countries [21]. About 90% of BC diagnoses are made in those of age 55 and older [2]. The mean age of patients in the United States diagnosed with BC is 73 years with 90% of patients being over 55 years old [23].

We included in the study Caucasian men over age 45. The mean age of patients in this study is 67.31 years, which is in accordance with other authors.

4.1.2 Tobacco smoking

The risk of BC was three to four times higher in smokers or ex-smokers than in non-smokers [2,23,24]. The population attributable risk of BC for tobacco smoking is 50–65% in men [8,23]. BC risk occurrence following tobacco smoking is second, just after lung cancer risk occurrence [2].

The older age of onset of BC suggests a latency period of approximately 30 years from the initiation of smoking to the cancer diagnosis. However, smoking cessation has been shown to reduce the risk of BC by approximately 40% within 1–4 years, and complete return to baseline risk by 20 years. A meta-analysis of 14 studies showed increased risk of BC for 22% during lifetime for secondhand smoking exposure in non-smoking respondents if compared with unexposed non-smoking population [2].

In a high-risk group with a history of smoking of ≥40 pack-years recorded 3.3% respondents with a histologically confirmed BC and another 6.6% respondents with precancerous lesions [25]. The smokers among BC patients were heavier smokers (mean 43.5 pack-years) [24,26].

Our results show statistically significant correlations in tobacco smoking over 40 pack-years, while BC occurrence is in accordance with the findings of other authors.

4.1.3 Occupational exposure

According to the literature the most prominent BC carcinogens are aniline (mainly in azo dyes) and polycyclic aromatic hydrocarbons (PAHs) [6]. Chemical carcinogens also contributing to BC occurrence (needed more intensity and/or more duration of exposure) are PAHs, 2-naphthylamine, 4-aminobiphenyl, toluene, 2-chloroaniline, and metal working fluids. It should be noted that all fossil fuels and woods produce PAHs, especially during incomplete combustion. Risky occupations are tobacco workers, dye and paint workers, metal and rubber industry workers [14,2224].

Recent articles reported that people living nearby combustion, mining, mechanical/car manufacturing establishments, and power plants had an increased BC risk, regardless of employment (environmental exposure to aromatic amines, PAHs, vehicle exhaust, and heavy metals) [27]. For example, Saginala and coauthors, reported occupational or environmental toxins accounting for an estimated 20% of all BC cases [2].

Workers exposed to aromatic amines (anilines) or PAHs have 16–23% higher risk for BC occurrence than the unexposed. Larré and coworkers reported that about 4% of BC is attributable to occupational exposure. Cumberbatch and coauthors informed that occupational carcinogen exposure accounts for approximately 5–6% of BC occurrences [8,18].

The risk of BC occurrence persists for up to 30 or 40 years after occupational exposure [8,24]. In some cases 2 years’ exposure seems to be sufficient to increase one’s BC risk decades after exposure [2].

Our results are in accordance with the previous findings.

4.1.4 Heredity (BC or other malignancy present in the first four kinship degrees)

Saginala and coauthors (2022) reported that heritable genetic predispositions contributed in about 7% of BC cases. Larré and coworkers cited that heredity accounts for <2% of new BC cases, and close relatives with BC are more often in BC patients diagnosed at a younger age [8].

NAT2 is a slow acetylator which detoxifies aromatic amines, and GSTM1 is an enzyme included in the detoxification of other environmental carcinogens. Abnormalities in genes NAT2 and GSTM1 lead to longer exposure to carcinogens. Their expression through phenotype is extremely different [18,26]. But, Vickers and coworkers informed that family history did not discriminate satisfactorily, and even more family history might be dropped from the eligibility assessment [17].

This study showed statistically significant co-relations between BC occurrence in relatives up to fourth degree of kinships and BC patients.

4.1.5 Hematuria

Painless hematuria is the most common but not mandatory early BC sign in ≈85% of patients [25]. Four studies, each of them included over one thousand elderly men tested for hematuria either repeatedly or subsequently reported about 0.6–1.3% BC participants. Population-based screening studies of men (age over 50 years) reported that 16–24% of respondents had hematuria, while 32% of BC patients did not have hematuria (hematuria is intermittent in many patients) [8]. In sources obtained from 2,356 screened asymptomatic men over the age of 60 years, 474 men (20%) had dipstick hematuria of which 5.3% (17/319 who agreed to further evaluation) showed asymptomatic BC [23]. Finally, macroscopic hematuria was present in 17% of cases of BC while microscopic hematuria was present in 4% of BC cases [28].

Our study showed statistically significant correlations between BC occurrence and macrohematuria.

4.1.6 Limitations of the study

To the best of our knowledge limitations of this study are relatively small samples of cases (100 persons) and controls (100 persons). These numbers should be increased. Also, the presented model should be reproduced in other centres and confirmed in them, or in other studies.

5 Conclusion

Screening studies of high-risk populations will probably become routine and more accurate for prevention of BC, oesophageal cancer, and similar diseases with low incidence in the general population. We developed a BC prediction and selection model (described six variables) that offers physicians and public health workers an opportunity for easy and fast selection of the individuals with high risk for BC occurrence and BC asymptomatic patients (optimal selection at the population level). This study is the first part of the BC screening protocol study, and the second part of the BC screening protocol study is ongoing (simple chemical analysis of urine).

Acknowledgements

The authors are thankful to the staff of the Urology Clinic at the Military Medical Academy in Belgrade. Special gratitude goes to the Chief of the Clinic Prof. Dr Predrag Aleksic, Dr Marko Maksic, Dr Ljubinko Petkovic (temporarily had been present at the Clinic), and Mrs Sonja Avramovic Lalovic. The authors are also thankful to Profs Milan Petronijevic and Zorica Brdareska, and Dr Radenko Vukic for support in interviewing the controls.

  1. Funding information: Authors state no funding involved.

  2. Author contributions: Both authors were included in conception of the manuscript, performance of work, interpretation of data, and writing article. Both authors had access to the data.

  3. Conflict of interest: Authors state no conflict of interest.

  4. Data availability statement: All data generated or analysed during this study are included in this published article (and its supplementary information files).

References

[1] Richters A, Aben K, Kiemeney L. The global burden of urinary bladder cancer: an update. World J Urol. 2020;38(8):1895–904.10.1007/s00345-019-02984-4Search in Google Scholar PubMed PubMed Central

[2] Saginala K, Barsouk A, Aluru JS, Rawla P, Padala SA, Barsouk A. Epidemiology of bladder cancer. Med Sci (Basel). 2020;8(1):15.10.3390/medsci8010015Search in Google Scholar PubMed PubMed Central

[3] Ebrahimi H, Amini E, Pishgar F, Moghaddam SS, Nabavizadeh B, Rostamabadi Y, et al. Global, regional and national burden of bladder cancer, 1990 to 2016: results from the GBD Study 2016. J Urol. 2019;201(5):893–901.10.1097/JU.0000000000000025Search in Google Scholar PubMed

[4] http://population.city/world/ (accessed 04 March 2022).Search in Google Scholar

[5] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.10.3322/caac.21660Search in Google Scholar PubMed

[6] Radosavljević V, Belojević G. Shortages in bladder cancer etiology research and a model of its prevention. Tumori. 2014;100(1):1–8.Search in Google Scholar

[7] Sanli O, Lotan Y. Current approaches for identifying high-risk non-muscle invasive bladder cancer. Expert Rev Anticancer Ther. 2018;18(3):223–35.10.1080/14737140.2018.1432358Search in Google Scholar PubMed

[8] Larré S, Catto JWF, Cookson MS, Messing EM, Shariat SF, Soloway MS, et al. Screening for bladder cancer: rationale, limitations, whom to target, and perspectives. Eur Urol. 2013;63(6):1049–58.10.1016/j.eururo.2012.12.062Search in Google Scholar PubMed

[9] Ng K, Stenzl A, Sharma A, Vasdev N. Urinary biomarkers in bladder cancer: a review of the current landscape and future directions. Urol Oncol. 2021;39(1):41–51.10.1016/j.urolonc.2020.08.016Search in Google Scholar PubMed

[10] Mamdouh S, Sherif H, Romeih M, Elesaily K. Urine micro-RNA signature as a potential non-invasive diagnostic biomarker in bladder cancer. Asian Pac J Cancer Prev. 2023;24(1):121–31.10.31557/APJCP.2023.24.1.121Search in Google Scholar PubMed PubMed Central

[11] Wang G, Jin W, Xu Z, Ju L, Shan D, Li S, et al. Urine-based liquid biopsy in bladder cancer: opportunities and challenges. Clin Transl Disc. 2023;3:e176. 10.1002/ctd2.176.Search in Google Scholar

[12] Ward DG, Baxter L, Ott S, Gordon NS, Wang J, Patel P, et al. Bladder Path Trial Management Group. Highly sensitive and specific detection of bladder cancer via targeted ultra-deep sequencing of urinary DNA. Eur Urol Oncol. 2023;6:67–75.10.1016/j.euo.2022.03.005Search in Google Scholar PubMed

[13] Schmitz-Dräger BJ, Droller M, Lokeshwar VB, Lotan Y, Hudson MA, van Rhijnet BW, et al. Molecular markers for bladder cancer screening, early diagnosis, and surveillance: the WHO/ICUD consensus. Urol Int. 2015;94(1):1–24.10.1159/000369357Search in Google Scholar PubMed

[14] IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Some non-heterocyclic polycyclic aromatic hydrocarbons and some related exposures. 1st edn. Lyon, FR: International Agency for Research on Cancer; 2010.Search in Google Scholar

[15] IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Chemical agents and related occupations. 1st edn. Lyon, FR: International Agency for Research on Cancer; 2012.Search in Google Scholar

[16] IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Re-evaluation of some organic chemicals, hydrazine and hydrogen peroxide. 1st edn. Lyon, FR: International Agency for Research on Cancer; 1999.Search in Google Scholar

[17] Vickers AJ, Bennette C, Kibel AS, Black A, Izmirlian G, Stephenson AJ, et al. Who should be included in a clinical trial of screening for bladder cancer? Cancer. 2013;119(1):143–9.10.1002/cncr.27692Search in Google Scholar PubMed PubMed Central

[18] Cumberbatch M, Noon A; on behalf of the EAU Young Academic Urologists—Urothelial Cancer Working party. Epidemiology, aetiology and screening of bladder cancer. Transl Androl Urol. 2019;8(1):5–11.10.21037/tau.2018.09.11Search in Google Scholar PubMed PubMed Central

[19] Chen W, Li H, Ren J, Zheng R, Shi J, Li J, et al. Selection of high-risk individuals for esophageal cancer screening: a prediction model of esophageal squamous cell carcinoma based on a multicenter screening cohort in rural China. Int J Cancer. 2021;148(2):329–39.10.1002/ijc.33208Search in Google Scholar PubMed

[20] Li H, Ding C, Zeng H, Zheng R, Cao M, Ren J, et al. Improved esophageal squamous cell carcinoma screening effectiveness by risk-stratified endoscopic screening: evidence from high-risk areas in China. Cancer Commun. 2021;41(8):715–25.10.1002/cac2.12186Search in Google Scholar PubMed PubMed Central

[21] Huang C-Y, Wang S-C, Chan L, Hsieh T-Y, Sung W-W, Chen S-L, et al. Gender differences in trends of bladder cancer mortality-to-incidence ratios according to health expenditure in 55 countries. PLoS One. 2021;16(2):e0244510.10.1371/journal.pone.0244510Search in Google Scholar PubMed PubMed Central

[22] Cumberbatch M, Jubber I, Black P, Black PC, Esperto F, Figueroa JD, et al.Epidemiology of bladder cancer: a systematic review and contemporary update of risk factors in 2018. Eur Urol. 2018;74(6):784–95.10.1016/j.eururo.2018.09.001Search in Google Scholar PubMed

[23] Cooley LF, Meeks JJ. Strategies for bladder cancer screening. In: Bjurlin MA, Matulewicz RS, editors. Comprehensive diagnostic approach to bladder cancer. Heidelberg: Springer; 2021. p. 45–53.10.1007/978-3-030-82048-0_3Search in Google Scholar

[24] Wu X, Lin J, Grossman HB, Gu J, Etzel CJ, Amos CI, et al. Projecting individualized probabilities of developing bladder cancer in white individuals. J Clin Oncol. 2007;25(31):4974–81.10.1200/JCO.2007.10.7557Search in Google Scholar PubMed

[25] Steiner H, Bergmeister M, Verdorfer I, Granig T, Mikuz G, Bartsch G, et al. Early results of bladder-cancer screening in a high-risk population of heavy smokers. BJU Int. 2008;102(3):291–6.10.1111/j.1464-410X.2008.07596.xSearch in Google Scholar PubMed

[26] Lotan Y, Svatek R, Malats N. Screening for bladder cancer: a perspective. World J Urol. 2008;26(1):13–8.10.1007/s00345-007-0223-2Search in Google Scholar PubMed

[27] Stringer L, Ly TL, Morena NV, Hewitt CM, Haan M, Power N, et al. Assessing geographic and industry-related trends in bladder cancer in Ontario: a population-based study. Can Urol Assoc J. 2021;16(2):E82–7.10.5489/cuaj.7263Search in Google Scholar PubMed PubMed Central

[28] Okubo R, Hoshi S-L, Kimura T, Kondo M, Asahi K, Iseki C, et al. Cost-efectiveness of mass screening for dipstick hematuria in Japan. Clin Exp Nephrol. 2022;26(5):398–412.10.1007/s10157-021-02170-0Search in Google Scholar PubMed

Received: 2022-11-02
Revised: 2023-04-03
Accepted: 2023-05-15
Published Online: 2023-06-16

© 2023 the author(s), published by De Gruyter

This work is licensed under the Creative Commons Attribution 4.0 International License.

Articles in the same Issue

  1. Research Articles
  2. Exosomes derived from mesenchymal stem cells overexpressing miR-210 inhibits neuronal inflammation and contribute to neurite outgrowth through modulating microglia polarization
  3. Current situation of acute ST-segment elevation myocardial infarction in a county hospital chest pain center during an epidemic of novel coronavirus pneumonia
  4. circ-IARS depletion inhibits the progression of non-small-cell lung cancer by circ-IARS/miR-1252-5p/HDGF ceRNA pathway
  5. circRNA ITGA7 restrains growth and enhances radiosensitivity by up-regulating SMAD4 in colorectal carcinoma
  6. WDR79 promotes aerobic glycolysis of pancreatic ductal adenocarcinoma (PDAC) by the suppression of SIRT4
  7. Up-regulation of collagen type V alpha 2 (COL5A2) promotes malignant phenotypes in gastric cancer cell via inducing epithelial–mesenchymal transition (EMT)
  8. Inhibition of TERC inhibits neural apoptosis and inflammation in spinal cord injury through Akt activation and p-38 inhibition via the miR-34a-5p/XBP-1 axis
  9. 3D-printed polyether-ether-ketone/n-TiO2 composite enhances the cytocompatibility and osteogenic differentiation of MC3T3-E1 cells by downregulating miR-154-5p
  10. Propofol-mediated circ_0000735 downregulation restrains tumor growth by decreasing integrin-β1 expression in non-small cell lung cancer
  11. PVT1/miR-16/CCND1 axis regulates gastric cancer progression
  12. Silencing of circ_002136 sensitizes gastric cancer to paclitaxel by targeting the miR-16-5p/HMGA1 axis
  13. Short-term outcomes after simultaneous gastrectomy plus cholecystectomy in gastric cancer: A pooling up analysis
  14. SCARA5 inhibits oral squamous cell carcinoma via inactivating the STAT3 and PI3K/AKT signaling pathways
  15. Molecular mechanism by which the Notch signaling pathway regulates autophagy in a rat model of pulmonary fibrosis in pigeon breeder’s lung
  16. lncRNA TPT1-AS1 promotes cell migration and invasion in esophageal squamous-cell carcinomas by regulating the miR-26a/HMGA1 axis
  17. SIRT1/APE1 promotes the viability of gastric cancer cells by inhibiting p53 to suppress ferroptosis
  18. Glycoprotein non-metastatic melanoma B interacts with epidermal growth factor receptor to regulate neural stem cell survival and differentiation
  19. Treatments for brain metastases from EGFR/ALK-negative/unselected NSCLC: A network meta-analysis
  20. Association of osteoporosis and skeletal muscle loss with serum type I collagen carboxyl-terminal peptide β glypeptide: A cross-sectional study in elder Chinese population
  21. circ_0000376 knockdown suppresses non-small cell lung cancer cell tumor properties by the miR-545-3p/PDPK1 pathway
  22. Delivery in a vertical birth chair supported by freedom of movement during labor: A randomized control trial
  23. UBE2J1 knockdown promotes cell apoptosis in endometrial cancer via regulating PI3K/AKT and MDM2/p53 signaling
  24. Metabolic resuscitation therapy in critically ill patients with sepsis and septic shock: A pilot prospective randomized controlled trial
  25. Lycopene ameliorates locomotor activity and urinary frequency induced by pelvic venous congestion in rats
  26. UHRF1-induced connexin26 methylation is involved in hearing damage triggered by intermittent hypoxia in neonatal rats
  27. LINC00511 promotes melanoma progression by targeting miR-610/NUCB2
  28. Ultra-high-performance liquid chromatography-tandem mass spectrometry analysis of serum metabolomic characteristics in people with different vitamin D levels
  29. Role of Jumonji domain-containing protein D3 and its inhibitor GSK-J4 in Hashimoto’s thyroiditis
  30. circ_0014736 induces GPR4 to regulate the biological behaviors of human placental trophoblast cells through miR-942-5p in preeclampsia
  31. Monitoring of sirolimus in the whole blood samples from pediatric patients with lymphatic anomalies
  32. Effects of osteogenic growth peptide C-terminal pentapeptide and its analogue on bone remodeling in an osteoporosis rat model
  33. A novel autophagy-related long non-coding RNAs signature predicting progression-free interval and I-131 therapy benefits in papillary thyroid carcinoma
  34. WGCNA-based identification of potential targets and pathways in response to treatment in locally advanced breast cancer patients
  35. Radiomics model using preoperative computed tomography angiography images to differentiate new from old emboli of acute lower limb arterial embolism
  36. Dysregulated lncRNAs are involved in the progress of myocardial infarction by constructing regulatory networks
  37. Single-arm trial to evaluate the efficacy and safety of baclofen in treatment of intractable hiccup caused by malignant tumor chemotherapy
  38. Genetic polymorphisms of MRPS30-DT and NINJ2 may influence lung cancer risk
  39. Efficacy of immune checkpoint inhibitors in patients with KRAS-mutant advanced non-small cell lung cancer: A retrospective analysis
  40. Pyroptosis-based risk score predicts prognosis and drug sensitivity in lung adenocarcinoma
  41. Upregulation of lncRNA LANCL1-AS1 inhibits the progression of non-small-cell lung cancer via the miR-3680-3p/GMFG axis
  42. CircRANBP17 modulated KDM1A to regulate neuroblastoma progression by sponging miR-27b-3p
  43. Exosomal miR-93-5p regulated the progression of osteoarthritis by targeting ADAMTS9
  44. Downregulation of RBM17 enhances cisplatin sensitivity and inhibits cell invasion in human hypopharyngeal cancer cells
  45. HDAC5-mediated PRAME regulates the proliferation, migration, invasion, and EMT of laryngeal squamous cell carcinoma via the PI3K/AKT/mTOR signaling pathway
  46. The association between sleep duration, quality, and nonalcoholic fatty liver disease: A cross-sectional study
  47. Myostatin silencing inhibits podocyte apoptosis in membranous nephropathy through Smad3/PKA/NOX4 signaling pathway
  48. A novel long noncoding RNA AC125257.1 facilitates colorectal cancer progression by targeting miR-133a-3p/CASC5 axis
  49. Impact of omicron wave and associated control measures in Shanghai on health management and psychosocial well-being of patients with chronic conditions
  50. Clinicopathological characteristics and prognosis of young patients aged ≤45 years old with non-small cell lung cancer
  51. TMT-based comprehensive proteomic profiling identifies serum prognostic signatures of acute myeloid leukemia
  52. The dose limits of teeth protection for patients with nasopharyngeal carcinoma undergoing radiotherapy based on the early oral health-related quality of life
  53. miR-30b-5p targeting GRIN2A inhibits hippocampal damage in epilepsy
  54. Long non-coding RNA AL137789.1 promoted malignant biological behaviors and immune escape of pancreatic carcinoma cells
  55. IRF6 and FGF1 polymorphisms in non-syndromic cleft lip with or without cleft palate in the Polish population
  56. Comprehensive analysis of the role of SFXN family in breast cancer
  57. Efficacy of bronchoscopic intratumoral injection of endostar and cisplatin in lung squamous cell carcinoma patients underwent conventional chemoradiotherapy
  58. Silencing of long noncoding RNA MIAT inhibits the viability and proliferation of breast cancer cells by promoting miR-378a-5p expression
  59. AG1024, an IGF-1 receptor inhibitor, ameliorates renal injury in rats with diabetic nephropathy via the SOCS/JAK2/STAT pathway
  60. Downregulation of KIAA1199 alleviated the activation, proliferation, and migration of hepatic stellate cells by the inhibition of epithelial–mesenchymal transition
  61. Exendin-4 regulates the MAPK and WNT signaling pathways to alleviate the osteogenic inhibition of periodontal ligament stem cells in a high glucose environment
  62. Inhibition of glycolysis represses the growth and alleviates the endoplasmic reticulum stress of breast cancer cells by regulating TMTC3
  63. The function of lncRNA EMX2OS/miR-653-5p and its regulatory mechanism in lung adenocarcinoma
  64. Tectorigenin alleviates the apoptosis and inflammation in spinal cord injury cell model through inhibiting insulin-like growth factor-binding protein 6
  65. Ultrasound examination supporting CT or MRI in the evaluation of cervical lymphadenopathy in patients with irradiation-treated head and neck cancer
  66. F-box and WD repeat domain containing 7 inhibits the activation of hepatic stellate cells by degrading delta-like ligand 1 to block Notch signaling pathway
  67. Knockdown of circ_0005615 enhances the radiosensitivity of colorectal cancer by regulating the miR-665/NOTCH1 axis
  68. Long noncoding RNA Mhrt alleviates angiotensin II-induced cardiac hypertrophy phenotypes by mediating the miR-765/Wnt family member 7B pathway
  69. Effect of miR-499-5p/SOX6 axis on atrial fibrosis in rats with atrial fibrillation
  70. Cholesterol induces inflammation and reduces glucose utilization
  71. circ_0004904 regulates the trophoblast cell in preeclampsia via miR-19b-3p/ARRDC3 axis
  72. NECAB3 promotes the migration and invasion of liver cancer cells through HIF-1α/RIT1 signaling pathway
  73. The poor performance of cardiovascular risk scores in identifying patients with idiopathic inflammatory myopathies at high cardiovascular risk
  74. miR-2053 inhibits the growth of ovarian cancer cells by downregulating SOX4
  75. Nucleophosmin 1 associating with engulfment and cell motility protein 1 regulates hepatocellular carcinoma cell chemotaxis and metastasis
  76. α-Hederin regulates macrophage polarization to relieve sepsis-induced lung and liver injuries in mice
  77. Changes of microbiota level in urinary tract infections: A meta-analysis
  78. Identification of key enzalutamide-resistance-related genes in castration-resistant prostate cancer and verification of RAD51 functions
  79. Falls during oxaliplatin-based chemotherapy for gastrointestinal malignancies – (lessons learned from) a prospective study
  80. Outcomes of low-risk birth care during the Covid-19 pandemic: A cohort study from a tertiary care center in Lithuania
  81. Vitamin D protects intestines from liver cirrhosis-induced inflammation and oxidative stress by inhibiting the TLR4/MyD88/NF-κB signaling pathway
  82. Integrated transcriptome analysis identifies APPL1/RPS6KB2/GALK1 as immune-related metastasis factors in breast cancer
  83. Genomic analysis of immunogenic cell death-related subtypes for predicting prognosis and immunotherapy outcomes in glioblastoma multiforme
  84. Circular RNA Circ_0038467 promotes the maturation of miRNA-203 to increase lipopolysaccharide-induced apoptosis of chondrocytes
  85. An economic evaluation of fine-needle cytology as the primary diagnostic tool in the diagnosis of lymphadenopathy
  86. Midazolam impedes lung carcinoma cell proliferation and migration via EGFR/MEK/ERK signaling pathway
  87. Network pharmacology combined with molecular docking and experimental validation to reveal the pharmacological mechanism of naringin against renal fibrosis
  88. PTPN12 down-regulated by miR-146b-3p gene affects the malignant progression of laryngeal squamous cell carcinoma
  89. miR-141-3p accelerates ovarian cancer progression and promotes M2-like macrophage polarization by targeting the Keap1-Nrf2 pathway
  90. lncRNA OIP5-AS1 attenuates the osteoarthritis progression in IL-1β-stimulated chondrocytes
  91. Overexpression of LINC00607 inhibits cell growth and aggressiveness by regulating the miR-1289/EFNA5 axis in non-small-cell lung cancer
  92. Subjective well-being in informal caregivers during the COVID-19 pandemic
  93. Nrf2 protects against myocardial ischemia-reperfusion injury in diabetic rats by inhibiting Drp1-mediated mitochondrial fission
  94. Unfolded protein response inhibits KAT2B/MLKL-mediated necroptosis of hepatocytes by promoting BMI1 level to ubiquitinate KAT2B
  95. Bladder cancer screening: The new selection and prediction model
  96. circNFATC3 facilitated the progression of oral squamous cell carcinoma via the miR-520h/LDHA axis
  97. Prone position effect in intensive care patients with SARS-COV-2 pneumonia
  98. Clinical observation on the efficacy of Tongdu Tuina manipulation in the treatment of primary enuresis in children
  99. Dihydroartemisinin ameliorates cerebral I/R injury in rats via regulating VWF and autophagy-mediated SIRT1/FOXO1 pathway
  100. Knockdown of circ_0113656 assuages oxidized low-density lipoprotein-induced vascular smooth muscle cell injury through the miR-188-3p/IGF2 pathway
  101. Low Ang-(1–7) and high des-Arg9 bradykinin serum levels are correlated with cardiovascular risk factors in patients with COVID-19
  102. Effect of maternal age and body mass index on induction of labor with oral misoprostol for premature rupture of membrane at term: A retrospective cross-sectional study
  103. Potential protective effects of Huanglian Jiedu Decoction against COVID-19-associated acute kidney injury: A network-based pharmacological and molecular docking study
  104. Clinical significance of serum MBD3 detection in girls with central precocious puberty
  105. Clinical features of varicella-zoster virus caused neurological diseases detected by metagenomic next-generation sequencing
  106. Collagen treatment of complex anorectal fistula: 3 years follow-up
  107. LncRNA CASC15 inhibition relieves renal fibrosis in diabetic nephropathy through down-regulating SP-A by sponging to miR-424
  108. Efficacy analysis of empirical bismuth quadruple therapy, high-dose dual therapy, and resistance gene-based triple therapy as a first-line Helicobacter pylori eradication regimen – An open-label, randomized trial
  109. SMOC2 plays a role in heart failure via regulating TGF-β1/Smad3 pathway-mediated autophagy
  110. A prospective cohort study of the impact of chronic disease on fall injuries in middle-aged and older adults
  111. circRNA THBS1 silencing inhibits the malignant biological behavior of cervical cancer cells via the regulation of miR-543/HMGB2 axis
  112. hsa_circ_0000285 sponging miR-582-3p promotes neuroblastoma progression by regulating the Wnt/β-catenin signaling pathway
  113. Long non-coding RNA GNAS-AS1 knockdown inhibits proliferation and epithelial–mesenchymal transition of lung adenocarcinoma cells via the microRNA-433-3p/Rab3A axis
  114. lncRNA UCA1 regulates miR-132/Lrrfip1 axis to promote vascular smooth muscle cell proliferation
  115. Twenty-four-color full spectrum flow cytometry panel for minimal residual disease detection in acute myeloid leukemia
  116. Hsa-miR-223-3p participates in the process of anthracycline-induced cardiomyocyte damage by regulating NFIA gene
  117. Anti-inflammatory effect of ApoE23 on Salmonella typhimurium-induced sepsis in mice
  118. Analysis of somatic mutations and key driving factors of cervical cancer progression
  119. Hsa_circ_0028007 regulates the progression of nasopharyngeal carcinoma through the miR-1179/SQLE axis
  120. Variations in sexual function after laparoendoscopic single-site hysterectomy in women with benign gynecologic diseases
  121. Effects of pharmacological delay with roxadustat on multi-territory perforator flap survival in rats
  122. Analysis of heroin effects on calcium channels in rat cardiomyocytes based on transcriptomics and metabolomics
  123. Risk factors of recurrent bacterial vaginosis among women of reproductive age: A cross-sectional study
  124. Alkbh5 plays indispensable roles in maintaining self-renewal of hematopoietic stem cells
  125. Study to compare the effect of casirivimab and imdevimab, remdesivir, and favipiravir on progression and multi-organ function of hospitalized COVID-19 patients
  126. Correlation between microvessel maturity and ISUP grades assessed using contrast-enhanced transrectal ultrasonography in prostate cancer
  127. The protective effect of caffeic acid phenethyl ester in the nephrotoxicity induced by α-cypermethrin
  128. Norepinephrine alleviates cyclosporin A-induced nephrotoxicity by enhancing the expression of SFRP1
  129. Effect of RUNX1/FOXP3 axis on apoptosis of T and B lymphocytes and immunosuppression in sepsis
  130. The function of Foxp1 represses β-adrenergic receptor transcription in the occurrence and development of bladder cancer through STAT3 activity
  131. Risk model and validation of carbapenem-resistant Klebsiella pneumoniae infection in patients with cerebrovascular disease in the ICU
  132. Calycosin protects against chronic prostatitis in rats via inhibition of the p38MAPK/NF-κB pathway
  133. Pan-cancer analysis of the PDE4DIP gene with potential prognostic and immunotherapeutic values in multiple cancers including acute myeloid leukemia
  134. The safety and immunogenicity to inactivated COVID-19 vaccine in patients with hyperlipemia
  135. Circ-UBR4 regulates the proliferation, migration, inflammation, and apoptosis in ox-LDL-induced vascular smooth muscle cells via miR-515-5p/IGF2 axis
  136. Clinical characteristics of current COVID-19 rehabilitation outpatients in China
  137. Luteolin alleviates ulcerative colitis in rats via regulating immune response, oxidative stress, and metabolic profiling
  138. miR-199a-5p inhibits aortic valve calcification by targeting ATF6 and GRP78 in valve interstitial cells
  139. The application of iliac fascia space block combined with esketamine intravenous general anesthesia in PFNA surgery of the elderly: A prospective, single-center, controlled trial
  140. Elevated blood acetoacetate levels reduce major adverse cardiac and cerebrovascular events risk in acute myocardial infarction
  141. The effects of progesterone on the healing of obstetric anal sphincter damage in female rats
  142. Identification of cuproptosis-related genes for predicting the development of prostate cancer
  143. Lumican silencing ameliorates β-glycerophosphate-mediated vascular smooth muscle cell calcification by attenuating the inhibition of APOB on KIF2C activity
  144. Targeting PTBP1 blocks glutamine metabolism to improve the cisplatin sensitivity of hepatocarcinoma cells through modulating the mRNA stability of glutaminase
  145. A single center prospective study: Influences of different hip flexion angles on the measurement of lumbar spine bone mineral density by dual energy X-ray absorptiometry
  146. Clinical analysis of AN69ST membrane continuous venous hemofiltration in the treatment of severe sepsis
  147. Antibiotics therapy combined with probiotics administered intravaginally for the treatment of bacterial vaginosis: A systematic review and meta-analysis
  148. Construction of a ceRNA network to reveal a vascular invasion associated prognostic model in hepatocellular carcinoma
  149. A pan-cancer analysis of STAT3 expression and genetic alterations in human tumors
  150. A prognostic signature based on seven T-cell-related cell clustering genes in bladder urothelial carcinoma
  151. Pepsin concentration in oral lavage fluid of rabbit reflux model constructed by dilating the lower esophageal sphincter
  152. The antihypertensive felodipine shows synergistic activity with immune checkpoint blockade and inhibits tumor growth via NFAT1 in LUSC
  153. Tanshinone IIA attenuates valvular interstitial cells’ calcification induced by oxidized low density lipoprotein via reducing endoplasmic reticulum stress
  154. AS-IV enhances the antitumor effects of propofol in NSCLC cells by inhibiting autophagy
  155. Establishment of two oxaliplatin-resistant gallbladder cancer cell lines and comprehensive analysis of dysregulated genes
  156. Trial protocol: Feasibility of neuromodulation with connectivity-guided intermittent theta-burst stimulation for improving cognition in multiple sclerosis
  157. LncRNA LINC00592 mediates the promoter methylation of WIF1 to promote the development of bladder cancer
  158. Factors associated with gastrointestinal dysmotility in critically ill patients
  159. Mechanisms by which spinal cord stimulation intervenes in atrial fibrillation: The involvement of the endothelin-1 and nerve growth factor/p75NTR pathways
  160. Analysis of two-gene signatures and related drugs in small-cell lung cancer by bioinformatics
  161. Silencing USP19 alleviates cigarette smoke extract-induced mitochondrial dysfunction in BEAS-2B cells by targeting FUNDC1
  162. Menstrual irregularities associated with COVID-19 vaccines among women in Saudi Arabia: A survey during 2022
  163. Ferroptosis involves in Schwann cell death in diabetic peripheral neuropathy
  164. The effect of AQP4 on tau protein aggregation in neurodegeneration and persistent neuroinflammation after cerebral microinfarcts
  165. Activation of UBEC2 by transcription factor MYBL2 affects DNA damage and promotes gastric cancer progression and cisplatin resistance
  166. Analysis of clinical characteristics in proximal and distal reflux monitoring among patients with gastroesophageal reflux disease
  167. Exosomal circ-0020887 and circ-0009590 as novel biomarkers for the diagnosis and prediction of short-term adverse cardiovascular outcomes in STEMI patients
  168. Upregulated microRNA-429 confers endometrial stromal cell dysfunction by targeting HIF1AN and regulating the HIF1A/VEGF pathway
  169. Bibliometrics and knowledge map analysis of ultrasound-guided regional anesthesia
  170. Knockdown of NUPR1 inhibits angiogenesis in lung cancer through IRE1/XBP1 and PERK/eIF2α/ATF4 signaling pathways
  171. D-dimer trends predict COVID-19 patient’s prognosis: A retrospective chart review study
  172. WTAP affects intracranial aneurysm progression by regulating m6A methylation modification
  173. Using of endoscopic polypectomy in patients with diagnosed malignant colorectal polyp – The cross-sectional clinical study
  174. Anti-S100A4 antibody administration alleviates bronchial epithelial–mesenchymal transition in asthmatic mice
  175. Prognostic evaluation of system immune-inflammatory index and prognostic nutritional index in double expressor diffuse large B-cell lymphoma
  176. Prevalence and antibiogram of bacteria causing urinary tract infection among patients with chronic kidney disease
  177. Reactive oxygen species within the vaginal space: An additional promoter of cervical intraepithelial neoplasia and uterine cervical cancer development?
  178. Identification of disulfidptosis-related genes and immune infiltration in lower-grade glioma
  179. A new technique for uterine-preserving pelvic organ prolapse surgery: Laparoscopic rectus abdominis hysteropexy for uterine prolapse by comparing with traditional techniques
  180. Self-isolation of an Italian long-term care facility during COVID-19 pandemic: A comparison study on care-related infectious episodes
  181. A comparative study on the overlapping effects of clinically applicable therapeutic interventions in patients with central nervous system damage
  182. Low intensity extracorporeal shockwave therapy for chronic pelvic pain syndrome: Long-term follow-up
  183. The diagnostic accuracy of touch imprint cytology for sentinel lymph node metastases of breast cancer: An up-to-date meta-analysis of 4,073 patients
  184. Mortality associated with Sjögren’s syndrome in the United States in the 1999–2020 period: A multiple cause-of-death study
  185. CircMMP11 as a prognostic biomarker mediates miR-361-3p/HMGB1 axis to accelerate malignant progression of hepatocellular carcinoma
  186. Analysis of the clinical characteristics and prognosis of adult de novo acute myeloid leukemia (none APL) with PTPN11 mutations
  187. KMT2A maintains stemness of gastric cancer cells through regulating Wnt/β-catenin signaling-activated transcriptional factor KLF11
  188. Evaluation of placental oxygenation by near-infrared spectroscopy in relation to ultrasound maturation grade in physiological term pregnancies
  189. The role of ultrasonographic findings for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer
  190. Construction of immunogenic cell death-related molecular subtypes and prognostic signature in colorectal cancer
  191. Long-term prognostic value of high-sensitivity cardiac troponin-I in patients with idiopathic dilated cardiomyopathy
  192. Establishing a novel Fanconi anemia signaling pathway-associated prognostic model and tumor clustering for pediatric acute myeloid leukemia patients
  193. Integrative bioinformatics analysis reveals STAT2 as a novel biomarker of inflammation-related cardiac dysfunction in atrial fibrillation
  194. Adipose-derived stem cells repair radiation-induced chronic lung injury via inhibiting TGF-β1/Smad 3 signaling pathway
  195. Real-world practice of idiopathic pulmonary fibrosis: Results from a 2000–2016 cohort
  196. lncRNA LENGA sponges miR-378 to promote myocardial fibrosis in atrial fibrillation
  197. Diagnostic value of urinary Tamm-Horsfall protein and 24 h urine osmolality for recurrent calcium oxalate stones of the upper urinary tract: Cross-sectional study
  198. The value of color Doppler ultrasonography combined with serum tumor markers in differential diagnosis of gastric stromal tumor and gastric cancer
  199. The spike protein of SARS-CoV-2 induces inflammation and EMT of lung epithelial cells and fibroblasts through the upregulation of GADD45A
  200. Mycophenolate mofetil versus cyclophosphamide plus in patients with connective tissue disease-associated interstitial lung disease: Efficacy and safety analysis
  201. MiR-1278 targets CALD1 and suppresses the progression of gastric cancer via the MAPK pathway
  202. Metabolomic analysis of serum short-chain fatty acid concentrations in a mouse of MPTP-induced Parkinson’s disease after dietary supplementation with branched-chain amino acids
  203. Cimifugin inhibits adipogenesis and TNF-α-induced insulin resistance in 3T3-L1 cells
  204. Predictors of gastrointestinal complaints in patients on metformin therapy
  205. Prescribing patterns in patients with chronic obstructive pulmonary disease and atrial fibrillation
  206. A retrospective analysis of the effect of latent tuberculosis infection on clinical pregnancy outcomes of in vitro fertilization–fresh embryo transferred in infertile women
  207. Appropriateness and clinical outcomes of short sustained low-efficiency dialysis: A national experience
  208. miR-29 regulates metabolism by inhibiting JNK-1 expression in non-obese patients with type 2 diabetes mellitus and NAFLD
  209. Clinical features and management of lymphoepithelial cyst
  210. Serum VEGF, high-sensitivity CRP, and cystatin-C assist in the diagnosis of type 2 diabetic retinopathy complicated with hyperuricemia
  211. ENPP1 ameliorates vascular calcification via inhibiting the osteogenic transformation of VSMCs and generating PPi
  212. Significance of monitoring the levels of thyroid hormone antibodies and glucose and lipid metabolism antibodies in patients suffer from type 2 diabetes
  213. The causal relationship between immune cells and different kidney diseases: A Mendelian randomization study
  214. Interleukin 33, soluble suppression of tumorigenicity 2, interleukin 27, and galectin 3 as predictors for outcome in patients admitted to intensive care units
  215. Identification of diagnostic immune-related gene biomarkers for predicting heart failure after acute myocardial infarction
  216. Long-term administration of probiotics prevents gastrointestinal mucosal barrier dysfunction in septic mice partly by upregulating the 5-HT degradation pathway
  217. miR-192 inhibits the activation of hepatic stellate cells by targeting Rictor
  218. Diagnostic and prognostic value of MR-pro ADM, procalcitonin, and copeptin in sepsis
  219. Review Articles
  220. Prenatal diagnosis of fetal defects and its implications on the delivery mode
  221. Electromagnetic fields exposure on fetal and childhood abnormalities: Systematic review and meta-analysis
  222. Characteristics of antibiotic resistance mechanisms and genes of Klebsiella pneumoniae
  223. Saddle pulmonary embolism in the setting of COVID-19 infection: A systematic review of case reports and case series
  224. Vitamin C and epigenetics: A short physiological overview
  225. Ebselen: A promising therapy protecting cardiomyocytes from excess iron in iron-overloaded thalassemia patients
  226. Aspirin versus LMWH for VTE prophylaxis after orthopedic surgery
  227. Mechanism of rhubarb in the treatment of hyperlipidemia: A recent review
  228. Surgical management and outcomes of traumatic global brachial plexus injury: A concise review and our center approach
  229. The progress of autoimmune hepatitis research and future challenges
  230. METTL16 in human diseases: What should we do next?
  231. New insights into the prevention of ureteral stents encrustation
  232. VISTA as a prospective immune checkpoint in gynecological malignant tumors: A review of the literature
  233. Case Reports
  234. Mycobacterium xenopi infection of the kidney and lymph nodes: A case report
  235. Genetic mutation of SLC6A20 (c.1072T > C) in a family with nephrolithiasis: A case report
  236. Chronic hepatitis B complicated with secondary hemochromatosis was cured clinically: A case report
  237. Liver abscess complicated with multiple organ invasive infection caused by hematogenous disseminated hypervirulent Klebsiella pneumoniae: A case report
  238. Urokinase-based lock solutions for catheter salvage: A case of an upcoming kidney transplant recipient
  239. Two case reports of maturity-onset diabetes of the young type 3 caused by the hepatocyte nuclear factor 1α gene mutation
  240. Immune checkpoint inhibitor-related pancreatitis: What is known and what is not
  241. Does total hip arthroplasty result in intercostal nerve injury? A case report and literature review
  242. Clinicopathological characteristics and diagnosis of hepatic sinusoidal obstruction syndrome caused by Tusanqi – Case report and literature review
  243. Synchronous triple primary gastrointestinal malignant tumors treated with laparoscopic surgery: A case report
  244. CT-guided percutaneous microwave ablation combined with bone cement injection for the treatment of transverse metastases: A case report
  245. Malignant hyperthermia: Report on a successful rescue of a case with the highest temperature of 44.2°C
  246. Anesthetic management of fetal pulmonary valvuloplasty: A case report
  247. Rapid Communication
  248. Impact of COVID-19 lockdown on glycemic levels during pregnancy: A retrospective analysis
  249. Erratum
  250. Erratum to “Inhibition of miR-21 improves pulmonary vascular responses in bronchopulmonary dysplasia by targeting the DDAH1/ADMA/NO pathway”
  251. Erratum to: “Fer exacerbates renal fibrosis and can be targeted by miR-29c-3p”
  252. Retraction
  253. Retraction of “Study to compare the effect of casirivimab and imdevimab, remdesivir, and favipiravir on progression and multi-organ function of hospitalized COVID-19 patients”
  254. Retraction of “circ_0062491 alleviates periodontitis via the miR-142-5p/IGF1 axis”
  255. Retraction of “miR-223-3p alleviates TGF-β-induced epithelial-mesenchymal transition and extracellular matrix deposition by targeting SP3 in endometrial epithelial cells”
  256. Retraction of “SLCO4A1-AS1 mediates pancreatic cancer development via miR-4673/KIF21B axis”
  257. Retraction of “circRNA_0001679/miR-338-3p/DUSP16 axis aggravates acute lung injury”
  258. Retraction of “lncRNA ACTA2-AS1 inhibits malignant phenotypes of gastric cancer cells”
  259. Special issue Linking Pathobiological Mechanisms to Clinical Application for cardiovascular diseases
  260. Effect of cardiac rehabilitation therapy on depressed patients with cardiac insufficiency after cardiac surgery
  261. Special issue The evolving saga of RNAs from bench to bedside - Part I
  262. FBLIM1 mRNA is a novel prognostic biomarker and is associated with immune infiltrates in glioma
  263. Special Issue Computational Intelligence Methodologies Meets Recurrent Cancers - Part III
  264. Development of a machine learning-based signature utilizing inflammatory response genes for predicting prognosis and immune microenvironment in ovarian cancer
Downloaded on 10.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/med-2023-0723/html
Scroll to top button